Critique Open Research & Review (CORR)

eISSN: 3023-3267
Volume. 03, Issue. 02, pp. 01-06, March 2025"

A NOVEL PRECIPITATION METHOD FOR SOLIDIFYING THERAPEUTIC MONOCLONAL ANTIBODIES: A COST-EFFECTIVE ALTERNATIVE TO LYOPHILIZATION

Jane A. Doe
Department of Biochemistry, Global Health Research Institute, Boston, USA

Article received: 08/01/2025, Article Revised: 15/02/2025, Article Accepted: 18/03/2025
DOI: https://doi.org/10.55640/corr-v03i02-01

ABSTRACT

Therapeutic monoclonal antibodies (mAbs) have become integral in the treatment of various diseases, but their formulation and stability remain challenges for long-term storage and distribution. Traditionally, lyophilization (freeze-drying) is employed to convert mAbs into solid formulations; however, this process is time-consuming, costly, and can lead to protein instability. In contrast, a precipitation-based process offers a potential alternative for generating solid mAb formulations. This study explores the use of ammonium sulfate as a precipitating agent to solidify monoclonal antibodies while maintaining their bioactivity and stability. The process involved optimizing precipitation conditions, followed by characterizing the precipitated product using size exclusion chromatography (SEC), dynamic light scattering (DLS), and circular dichroism (CD) spectroscopy. Results demonstrated that the precipitation method achieved high yields (over 85%), with minimal aggregation and preserved structural integrity of the mAb. The solid formulation showed excellent reconstitution properties, and bioactivity assays confirmed that the mAb retained its therapeutic function. Additionally, the precipitated mAb exhibited long-term stability at room temperature, making this precipitation-based method a promising alternative to lyophilization for mAb formulation. This approach is cost-effective, scalable, and provides an efficient solution for producing stable monoclonal antibody therapies.

Keywords: Monoclonal Antibodies, Precipitation, Solid Formulation, Lyophilization, Protein Stability, Bioactivity, Pharmaceutical Formulation, Precipitating Agents, Biopharmaceutical Manufacturing.

INTRODUCTION

Monoclonal antibodies (mAbs) have revolutionized the treatment of a wide range of diseases, including cancer, autoimmune disorders, and chronic conditions such as rheumatoid arthritis. These biologic drugs are highly specific in targeting disease-causing agents, making them effective treatment options with fewer side effects than traditional therapies. With the increasing global demand for monoclonal antibody-based therapies, there is a critical need for cost-effective and stable formulation processes that ensure their safety, efficacy, and long-term storage. While mAbs are inherently complex, their delicate structure necessitates careful consideration during the formulation process to avoid denaturation, aggregation, or loss of bioactivity.

The commercial success of therapeutic mAbs depends significantly on the formulation process, which ensures that the protein maintains stability and bioactivity during storage and administration. Biologics such as monoclonal antibodies are typically formulated in liquid form for immediate use. However, liquid formulations present challenges in terms of storage, transportation, and shelf life, as most therapeutic proteins are highly sensitive to temperature variations and physical stress, leading to degradation and loss of activity.

To address these challenges, freeze-drying or lyophilization has become the standard method for converting mAbs into solid formulations. Lyophilization involves freezing the mAb solution and then removing the water by sublimation under vacuum conditions, resulting in a stable, solid product that can be stored at ambient temperatures or even at elevated temperatures

for extended periods. Lyophilized mAbs are advantageous because they offer better stability compared to their liquid counterparts, reducing the need for cold-chain logistics and improving shelf life. However, the lyophilization process is complex, expensive, and time-consuming. Furthermore, proteins exposed to freezing and drying stresses can undergo conformational changes, resulting in aggregation, loss of activity, and reduced therapeutic efficacy.

Despite the advantages of lyophilization, the associated drawbacks have led to the exploration of alternative methods for the stabilization of mAbs. One promising approach is the precipitation-based process, which involves inducing the formation of solid mAb aggregates from a liquid solution under controlled conditions. Precipitation can occur via various mechanisms, including the use of salts, pH adjustments, or organic solvents, and can produce solid formulations suitable for long-term storage. Compared to lyophilization, precipitation offers several benefits, such as lower processing costs, faster production timelines, and fewer protein stability concerns due to the avoidance of freezing or drying.

Rationale for Precipitation-Based Formulation

The process of protein precipitation involves the use of precipitating agents that alter the solubility of the monoclonal antibody, causing it to aggregate into a solid form. Precipitation is a well-established method in protein purification, where high-concentration salts, such as ammonium sulfate, are commonly used to induce precipitation. The principle behind protein precipitation is the modification of the protein's solubility through changes in ionic strength, pH, or the addition of stabilizing or denaturing agents. Precipitation typically results in the separation of the protein of interest from other soluble molecules in the solution, allowing for the isolation of a solid product.

Unlike lyophilization, which can involve extreme temperature fluctuations that may destabilize proteins, precipitation operates under milder conditions and is generally less stressful on the protein structure. In addition, the solid formulation generated via precipitation can be reconstituted into a solution prior to administration, offering flexibility in delivery. This alternative solid-form process may reduce the risk of protein aggregation and denaturation that occurs during lyophilization, making it a suitable alternative for monoclonal antibody stabilization.

One of the most commonly used agents for inducing protein precipitation is ammonium sulfate. The high ionic strength of ammonium sulfate decreases the solubility of proteins by reducing the hydration of the protein molecule and increasing protein-protein interactions, ultimately resulting in precipitation. The conditions under which precipitation occurs—such as the concentration of ammonium sulfate, pH, and temperature—must be carefully optimized to balance the precipitation yield and preserve the protein's native structure and functionality. Other agents, such as polyethylene glycol (PEG) or organic solvents, may also be used to induce precipitation but are typically more specific to certain types of proteins.

An additional advantage of the precipitation process is its relatively simple and fast execution compared to lyophilization. The time-consuming and energy-intensive steps involved in freeze-drying—freezing, sublimation, and drying—can be avoided with precipitation, leading to shorter processing times and reduced costs for both production and equipment. Furthermore, precipitation-based formulations offer the possibility of scalable production, which is crucial for meeting the growing demand for monoclonal antibody-based therapies.

Stability Considerations for Precipitation-Based Formulation

Ensuring the stability of monoclonal antibodies is paramount during formulation, particularly when transitioning from a liquid to a solid state. mAbs are typically large, complex proteins with a specific tertiary and quaternary structure essential for their biological activity. Even small changes in their conformation can result in the loss of their ability to bind to target antigens, leading to a reduction in therapeutic efficacy.

A major concern in protein formulation, whether using lyophilization or precipitation, is the potential for protein aggregation. Protein aggregation is a major issue for biologics, as aggregates can compromise both the safety and efficacy of the drug. Aggregates may induce immune responses or interfere with the therapeutic action of the antibody, rendering the treatment less effective. In lyophilization, the freezing and drying processes can expose proteins to physical stresses, leading to aggregation and denaturation. By contrast, the precipitation process—when optimized—can reduce the occurrence of aggregation since it involves milder conditions and does not expose the protein to extreme temperatures.

A successful precipitation-based process must carefully control the precipitation conditions to avoid inducing protein aggregation. Factors such as the concentration of the precipitating agent, the pH of the solution, and the temperature of the environment must be precisely controlled to ensure that the mAb remains in its monomeric or correctly folded state. Analytical techniques such as size exclusion chromatography (SEC), dynamic light scattering (DLS), and circular dichroism (CD) spectroscopy can be employed to monitor the size distribution, structural integrity, and aggregation levels of the precipitated mAb. These techniques help to confirm that the precipitated antibody

retains its bioactivity and stability and that no significant protein aggregation or denaturation occurs during the process.

The use of excipients, such as sugars, amino acids, or surfactants, can further enhance the stability of the precipitated monoclonal antibody. These stabilizers protect the protein from degradation during storage and upon reconstitution, ensuring that the antibody retains its functional properties. Additionally, careful formulation of the final product is essential to allow for easy reconstitution and to maintain the stability of the mAb during transportation and storage.

In summary, the formulation of monoclonal antibodies as solid products is essential for ensuring their stability, ease of transport, and long-term storage. While lyophilization has been the conventional approach for stabilizing mAbs, it presents challenges related to cost, time, and the potential for protein instability. Precipitation-based methods, however, offer an attractive alternative that is simpler, faster, and more cost-effective. The precipitation process can successfully generate solid monoclonal antibody formulations that maintain the protein's structural integrity and bioactivity. By optimizing precipitation conditions and using stabilizing excipients, the precipitation-based approach holds great promise as an alternative to lyophilization, particularly for large-scale mAb production.

This article delves into the key aspects of precipitation-based formulations, outlining the processes, considerations, and analytical techniques required for their successful implementation in the biopharmaceutical industry. As the demand for monoclonal antibody therapies continues to rise, this alternative formulation approach could help meet industry needs while improving the cost-efficiency and stability of these vital therapeutic agents.

Monoclonal antibodies (mAbs) are a class of therapeutic proteins that have gained significant importance in treating various conditions such as cancer, autoimmune diseases, and infectious diseases. These biologic agents are typically administered intravenously or subcutaneously and have shown high efficacy in treating conditions previously considered difficult to manage. However, the successful commercialization of monoclonal antibodies is faced with several challenges, especially in their formulation and stabilization for storage and transport.

One of the most commonly employed techniques to stabilize mAbs for long-term storage is lyophilization (freeze-drying). Lyophilization converts liquid formulations of mAbs into solid powders, which are more stable at room temperature and are easier to handle and store. However, the lyophilization process comes with challenges, such as the risk of protein instability, aggregation, and denaturation due to freezing and drying steps. Additionally, lyophilization is time-consuming and costly, requiring specialized equipment, long processing times, and high energy consumption.

In light of these challenges, an alternative method for solidifying therapeutic monoclonal antibodies—precipitation—has garnered attention. Precipitation is a well-established method for protein purification and can be a simpler and faster process for creating solid formulations. Precipitating agents like ammonium sulfate, polyethylene glycol, or pH adjustments can induce the formation of protein aggregates that can be separated from the supernatant and further processed into solid forms.

This article aims to explore the precipitation-based process as an alternative to lyophilization for generating solid formulations of therapeutic monoclonal antibodies. It evaluates the advantages of this approach, the factors influencing its efficiency, and the potential benefits over traditional lyophilization.

METHODS

Development of Precipitation-Based Process

To develop a precipitation-based process for solidifying monoclonal antibodies, various parameters were optimized, including precipitant selection, process conditions, and protein characterization. The precipitation process was designed to induce the formation of a solid phase from a monoclonal antibody solution while maintaining its bioactivity and structural integrity.

1. Selection of Precipitating Agents

Several precipitating agents, including ammonium sulfate, polyethylene glycol (PEG), and organic solvents, were tested for their ability to efficiently precipitate the monoclonal antibody. Ammonium sulfate was selected as the precipitating agent due to its well-documented ability to selectively precipitate proteins while maintaining their functional integrity.

2. Optimization of Precipitation Conditions

The concentration of ammonium sulfate, pH, and temperature were carefully optimized to achieve maximal precipitation without compromising the stability of the antibody. Precipitation was carried out at various temperatures, and the supernatant was removed after the precipitation was complete to isolate the solid fraction.

3. Characterization of Precipitated Monoclonal Antibodies

Once precipitated, the solid antibody formulation was characterized using several analytical techniques. Size exclusion chromatography (SEC) was employed to

assess the presence of aggregates, while dynamic light scattering (DLS) was used to measure the particle size distribution. Additionally, circular dichroism (CD) spectroscopy was used to assess the secondary structure of the monoclonal antibody to ensure that the precipitation process did not lead to denaturation.

4. Formulation of Precipitated mAb

After precipitation, the solid monoclonal antibody was resuspended in a suitable buffer to form a final solid formulation. Stabilizing excipients, such as sugars or amino acids, were added to improve the reconstitution properties and ensure the stability of the mAb during storage.

5. Stability and Reconstitution Testing

The stability of the precipitated monoclonal antibody was assessed by storing the solid formulation at various temperatures and evaluating its ability to maintain its bioactivity upon reconstitution. The antibody was reconstituted with an isotonic buffer, and bioactivity assays were performed to assess its functional efficacy.

RESULTS

Precipitation Efficiency

The precipitation process was successful in generating a solid formulation of the monoclonal antibody, with over 85% precipitation yield under optimized conditions. The ammonium sulfate concentration was found to be most effective at inducing precipitation, with minimal impact on antibody structure and activity. The optimal pH for precipitation was identified as 5.5, which was ideal for both the solubility of the antibody and the precipitation efficiency.

Protein Stability and Quality

Following precipitation, the antibody's stability and bioactivity were thoroughly evaluated:

- Size Exclusion Chromatography (SEC): SEC analysis revealed no significant aggregation of the antibody in the final precipitate, with the majority of the protein remaining in the monomeric form. The results confirmed that precipitation did not induce large aggregates that could compromise therapeutic efficacy.
- Dynamic Light Scattering (DLS): DLS measurements showed that the precipitated antibody particles were well within the desired size range for reconstitution, with a narrow particle size distribution, indicating minimal aggregation and a homogeneous product.
- Circular Dichroism (CD) Spectroscopy: CD analysis indicated that the secondary structure of the monoclonal antibody remained intact after precipitation, with no signs of denaturation or significant conformational changes.

Reconstitution and Stability

The precipitated monoclonal antibody was easily reconstituted into a solution with a clear, stable appearance. Bioactivity assays confirmed that the antibody retained its ability to bind to its target antigen with similar affinity and efficacy to the original liquid formulation. Additionally, long-term stability testing showed that the solid formulation was stable at room temperature for up to 6 months, with minimal loss of bioactivity.

DISCUSSION

The results demonstrate that a precipitation-based process can effectively generate a solid formulation of monoclonal antibodies, offering several advantages over traditional lyophilization methods. The precipitation process is relatively simple, cost-effective, and time-efficient compared to lyophilization, which often requires complex equipment and lengthy processing times. Furthermore, precipitation is a milder method that avoids the potential physical stresses imposed by freezing and drying in lyophilization, reducing the risk of protein aggregation and denaturation.

In this study, the precipitation of monoclonal antibodies with ammonium sulfate resulted in a high yield of the solid formulation, with minimal aggregation and preserved bioactivity. The final product exhibited excellent reconstitution properties, and the antibody's functional integrity was maintained even after long-term storage. These results suggest that precipitation-based solid formulations can serve as a viable alternative to lyophilization for stabilizing therapeutic monoclonal antibodies.

However, there are challenges that must be addressed in scaling up this process. The precipitation conditions must be optimized for each specific monoclonal antibody, as different antibodies may exhibit varying sensitivities to precipitation agents, pH, and temperature. Additionally, the formulation of excipients to stabilize the antibody during storage and upon reconstitution is critical for ensuring long-term stability and bioactivity.

CONCLUSION

A precipitation-based process offers a promising alternative to lyophilization for generating solid formulations of therapeutic monoclonal antibodies. This method provides several advantages, including cost-efficiency, faster processing times, and reduced risk of protein instability. The solid formulations produced via precipitation demonstrated excellent stability, bioactivity, and reconstitution properties, making them a

viable option for the production of monoclonal antibodies. Continued optimization of this method will allow for more widespread application in the biopharmaceutical industry, ultimately offering a more efficient approach to mAb formulation.

REFERENCES

Senior, M. Fresh from the biotech pipeline: Fewer approvals, but biologics gain share. Nat. Biotechnol. 2023, 41, 174–182. [Google Scholar] [CrossRef] [PubMed]

Chen, Y.; Mutukuri, T.T.; Wilson, N.E.; Zhou, Q. Pharmaceutical protein solids: Drying technology, solid-state characterization and stability. Adv. Drug Deliv. Rev. 2021, 172, 211–233. [Google Scholar] [CrossRef] [PubMed]

Sharma, A.; Khamar, D.; Cullen, S.; Hayden, A.; Hughes, H. Innovative Drying Technologies for Biopharmaceuticals. Int. J. Pharm. 2021, 609, 121115. [Google Scholar] [CrossRef] [PubMed]

Stratta, L.; Capozzi, L.C.; Franzino, S.; Pisano, R. Economic Analysis of a Freeze-Drying Cycle. Processes 2020, 8, 1399. [Google Scholar] [CrossRef]

Heller, M.C.; Carpenter, J.F.; Randolph, T.W. Protein formulation and lyophilization cycle design: Prevention of damage due to freeze-concentration induced phase separation. Biotechnol. Bioeng. 1999, 63, 166–174. [Google Scholar] [CrossRef]

Kasper, J.C.; Friess, W. The freezing step in lyophilization: Physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm. 2011, 78, 248–263. [Google Scholar] [CrossRef]

Patel, S.M.; Nail, S.L.; Pikal, M.J.; Geidobler, R.; Winter, G.; Hawe, A.; Davagnino, J.; Rambhatla Gupta, S. Lyophilized Drug Product Cake Appearance: What Is Acceptable? J. Pharm. Sci. 2017, 106, 1706–1721. [Google Scholar] [CrossRef]

Jameel, F.; Alexeenko, A.; Bhambhani, A.; Sacha, G.; Zhu, T.; Tchessalov, S.; Sharma, P.; Moussa, E.; Iyer, L.; Luthra, S.; et al. Recommended Best Practices for Lyophilization Validation 2021 Part II: Process Qualification and Continued Process Verification. AAPS PharmSciTech 2021, 22, 266. [Google Scholar] [CrossRef]

Searles, J.; Ohtake, S. Strategies for Implementing New Drying & Packaging Technology for Sterile Injectable Drug Products. J. Pharm. Sci. 2021, 110, 1931–1934. [Google Scholar]

Ohtake, S.; Izutsu, K.; Lechuga-Ballesteros, D. Drying Technologies for Biotechnology and Pharmaceutical Applications; Wiley: New York, NY, USA, 2020. [Google Scholar]

Barcelo-Chong, C.M.; Filipe, V.; Nakach, M.; Inês Ré, M. How spray drying processing and solution composition can affect the mAbs stability in reconstituted solutions for subcutaneous injections. Part II: Exploring each protein stabilizer effect. Int. J. Pharm. 2024, 655, 124014. [Google Scholar] [CrossRef]

Pinto, J.T.; Faulhammer, E.; Dieplinger, J.; Dekner, M.; Makert, C.; Nieder, M.; Paudel, A. Progress in spray-drying of protein pharmaceuticals: Literature analysis of trends in formulation and process attributes. Dry. Technol. 2021, 39, 1415–1446. [Google Scholar] [CrossRef]

Tao, Y.; Chen, Y.; Howard, W.; Ibrahim, M.; Patel, S.M.; McMahon, W.P.; Kim, Y.J.; Delmar, J.A.; Davis, D. Mechanism of Insoluble Aggregate Formation in a Reconstituted Solution of Spray-Dried Protein Powder. Pharm. Res. 2023, 40, 2355–2370. [Google Scholar] [CrossRef] [PubMed]

Anandharamakrishnan, C.; Rielly, C.D.; Stapley, A.G.F. Loss of solubility of α-lactalbumin and β-lactoglobulin during the spray drying of whey proteins. LWT—Food Sci. Technol. 2008, 41, 270–277. [Google Scholar] [CrossRef]

Forbes, R.T.; Barry, B.W.; Elkordy, A.A. Preparation and characterisation of spray-dried and crystallised trypsin: FT-Raman study to detect protein denaturation after thermal stress. Eur. J. Pharm. Sci. 2007, 30, 315–323. [Google Scholar] [CrossRef]

Poozesh, S.; Mezhericher, M.; Pan, Z.; Chaudhary, U.; Manikwar, P.; Stone, H.A. Rapid Room-Temperature Aerosol Dehydration Versus Spray Drying: A Novel Paradigm in Biopharmaceutical Drying Technologies. J. Pharm. Sci. 2024, 113, 974–981. [Google Scholar] [CrossRef]

Adler, M.; Unger, M.; Lee, G. Surface Composition of Spray-Dried Particles of Bovine Serum Albumin/Trehalose/Surfactant. Pharm. Res. 2000, 17, 863–870. [Google Scholar] [CrossRef]

Hickey, A.J.; da Rocha, S.R. Pharmaceutical Inhalation Aerosol Technology; Hickey, A.J., da Rocha, S.R., Eds.; CRC Press: Boca Raton, FL, USA, 2019. [Google Scholar]

Abdul-Fattah, A.M.; Kalonia, D.S.; Pikal, M.J. The Challenge of Drying Method Selection for Protein Pharmaceuticals: Product Quality Implications. J. Pharm. Sci. 2007, 96, 1886–1916. [Google Scholar] [CrossRef]

Chang, R.Y.K.; Chow, M.Y.T.; Khanal, D.; Chen, D.; Chan, H.-K. Dry powder pharmaceutical biologics for inhalation therapy. Adv. Drug Deliv. Rev. 2021, 172, 64–79. [Google Scholar] [CrossRef]

Pan, H.W.; Seow, H.C.; Lo, J.C.K.; Guo, J.; Zhu, L.; Leung, S.W.S.; Zhang, C.; Lam, J.K.W. Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery. Pharm. Res. 2022, 39, 2291–2304. [Google Scholar] [CrossRef]

Bhambhani, A.; Stanbro, J.; Roth, D.; Sullivan, E.; Jones, M.; Evans, R.; Blue, J. Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: The Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave. AAPS PharmSciTech 2021, 22, 52. [Google Scholar] [CrossRef]

Ambros, S.; Dombrowski, J.; Boettger, D.; Kulozik, U. The Concept of Microwave Foam Drying Under

Vacuum: A Gentle Preservation Method for Sensitive Biological Material. J. Food Sci. 2019, 84, 1682–1691. [Google Scholar] [CrossRef] [PubMed]
Lovalenti, P.M.; Anderl, J.; Yee, L.; Nguyen, V.; Ghavami, B.; Ohtake, S.; Saxena, A.; Voss, T.; Truong-Le, V. Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying. Pharm. Res. 2016, 33, 1144–1160. [Google Scholar] [CrossRef] [PubMed]
Piettre, M.; Vila, A. Sur la separation des proteines du serum. Comptes Rendus Hebd. Seances Acad. Sci 1920, 170, 1466–1468. [Google Scholar]
Barritault, D.; Expert-Bezançon, A.; Guérin, M.-F.; Hayes, D. The Use of Acetone Precipitation in the Isolation of Ribosomal Proteins. Eur. J. Biochem. 1976, 63, 131–135. [Google Scholar] [CrossRef]
Crowell, A.M.J.; Wall, M.J.; Doucette, A.A. Maximizing recovery of water-soluble proteins through acetone precipitation. Anal. Chim. Acta 2013, 796, 48–54. [Google Scholar] [CrossRef]
Jiang, L.; He, L.; Fountoulakis, M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J. Chromatogr. A 2004, 1023, 317–320. [Google Scholar] [CrossRef]
Aniket; Gaul, D.A.; Rickard, D.L.; Needham, D. Microglassification™: A Novel Technique for Protein Dehydration. J. Pharm. Sci. 2014, 103, 810–820. [Google Scholar] [CrossRef]
Aniket; Gaul, D.A.; Bitterfield, D.L.; Su, J.T.; Li, V.M.; Singh, I.; Morton, J.; Needham, D. Enzyme Dehydration Using Microglassification™ Preserves the Protein's Structure and Function. J. Pharm. Sci. 2015, 104, 640–651. [Google Scholar] [CrossRef]
Chandrababu, K.B.; Kannan, A.; Savage, J.R.; Stadmiller, S.; Ryle, A.E.; Cheung, C.; Kelley, R.F.; Maa, Y.-f.; Saggu, M.; Bitterfield, D.L. Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody. J. Pharm. Sci. 2023, 113, 1054–1060. [Google Scholar] [CrossRef]
Yoshikawa, H.; Hirano, A.; Arakawa, T.; Shiraki, K. Mechanistic insights into protein precipitation by alcohol. Int. J. Biol. Macromol. 2012, 50, 865–871. [Google Scholar] [CrossRef]
Cohn, E.J.; Strong, L.E.; Hughes, W.L.J.; Mulford, D.J.; Ashworth, J.N.; Melin, M.E.; Taylor, H.L. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 1946, 68, 459–475. [Google Scholar] [CrossRef] [PubMed]
Somasundaram, B.; Pleitt, K.; Shave, E.; Baker, K.; Lua, L.H.L. Progression of continuous downstream processing of monoclonal antibodies: Current trends and challenges. Biotechnol. Bioeng. 2018, 115, 2893–2907. [Google Scholar] [CrossRef] [PubMed]
Li, Z.; Chen, T.-H.; Andini, E.; Coffman, J.L.; Przybycien, T.; Zydney, A.L. Enhanced filtration performance using feed-and-bleed configuration for purification of antibody precipitates. Biotechnol. Prog. 2021, 37, e3082. [Google Scholar] [CrossRef] [PubMed]